Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its inclusion in the Russell 3000® and Russell 2000® Indexes, which became effective yesterday. This milestone marks a significant step …
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has launched a Phase 1a/1b clinical program to evaluate the safety and efficacy of ATI-052, an investigational bispecific anti-TSLP/IL-4R antibody that could …
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 Read MoreWAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis (AD). This randomized, …
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in two healthcare conferences in June:
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that CEO Neal Walker and other senior leaders will join a virtual fireside chat as part of the HC Wainwright “HCW@Home” …
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) released its financial results for the first quarter of 2025, alongside updates on its expanding immuno-inflammatory (I&I) pipeline and leadership changes. The …
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has named Jesse Hall, M.D., as its new Chief Medical Officer. Dr. Hall brings decades of expertise in medical and clinical development, …
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its participation in two scheduled healthcare conferences in March 2025, where the company’s leadership team will provide insights into its …
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its fourth quarter and full-year 2024 financial results, along with key pipeline advancements and corporate updates signaling a pivotal year ahead.
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 Read More